Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 25 26 27 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene 2016-12-01
Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II 2016-12-01
Roche–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech 2016-12-01
Valneva–France (govt): investment, 201612 existent Bpifrance is 2nd largest shareholder owning 9.6% 2016-12-01
Valneva–Grimaud: investment, 201612 existent Groupe Grimaud is largest shareholder owning 15.6% 2016-12-01
Valneva–MVM: investment, 201612 private placement €7.5m w 2.9m new shares at €2.6 to MVM plus acqu existing shares results in 7.5% MVM share 2016-12-01
Boehringer–ACD/Labs: cheminformatics, 201611– supply deployment of ACD/Spectrus platform by Boehringer in Europe + North America 2016-11-30
Evotec–Merck (DE): target discovery technology, 201611– collab agreements to combine Merck genome editing technologies w Evotec screening (LT) 2016-11-30
G7 Therapeutics–Sosei: investment, 201611– acquisition 100% for CHF12m in cash of G7 Therapeutics by Heptares 2016-11-30
Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy 2016-11-30
AudioCure Pharma–High-Tech Gründerfonds: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–MED-EL: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–SEVERAL: investment, 201611 financing round €9m from new investor MED-EL + existing investor HTGF + private investors 2016-11-29
GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services 2016-11-29
Jackson Laboratory–Agilent: grant, 201611– Thought Leader Award to Peter Robinson at Jackons Lab for Genomic Medicine for clinical genomics research 2016-11-28
Menarini–Chugai: cancer drug, 201611– license ww excl for class I PI3K inhibitor PA799 to Berlin-Chemie Menarini 2016-11-28
Themis Bioscience–SEVERAL: investment, 201611 financing round Series B €10m 2nd + final closing with additional €3m 2016-11-28
T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors 2016-11-23
Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug 2016-11-22
Horizon Discovery–Sophia Genetics: genomic cancer testing, 201611– collab €na integrating HDx Reference Standards w DDM Platform for NGS cancer tests 2016-11-17
Epigenomics–Cathay Fortune: investment, 201611 private placement €2.1m w 474.8k new shares at €4.52/share fully subscribed by Cathay Fortune 2016-11-16
HTG–Qiagen: investment, 201611 minority investment by Qiagen North American Holdings as part of CDx collaboration 2016-11-16
Qiagen–HTG: molecular companion diagnostics, 201611– collab developm complete NGS solution from biomarker to CDx test 2016-11-16
Thar Pharmaceuticals–Grünenthal: investment, 201611 acquisition of Thar by Grünenthal 2016-11-16
UroMems–SEVERAL: investment, 201611 financing round Series A €12m led by Wellington Partners 2016-11-16
MorphoSys–BVF Partners: investment, 201611 private placement totalling €115m incl €52.8m from BVF Partners acquiring 1.2m shares at €44/share 2016-11-15
MorphoSys–SEVERAL: investment, 201611 private placement €115m w 2.622m new shares at €44/share to European + North American institutional investors 2016-11-15
OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform 2016-11-15
Roche–SEVERAL: cancer immunotherapy, 201611– establishment of imCORE Network by Roche with 21 ww academic centers 2016-11-15
Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI 2016-11-10
Kaye Scholer–Arnold & Porter: investment, 201611–201701 merger into Arnold & Porter Kaye Scholer LLP 2016-11-10
Qiagen–Genohm: LIMS, –201610– collab developm GeneRead Link middleware to connect GeneReader NGS data with LIMS 2016-11-09
CureVac–SEVERAL: investment, 201611 financing $29.5m led by new investors LBBW Asset (for BWVÄZT) + Landeskreditbank BW 2016-11-08
Epigenomics–SEVERAL: investment, 201611 private placement €5m 1.035m new shares at €4.83/share to UChip Technology Ltd + BioChain (BVI) Inc 2016-11-07
Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution 2016-11-07
Aimmune Therapeutics–Nestlé: investment, 201611 equity investment $145m w 7.6m shares at $19.2/share by Nestlé Health Science 2016-11-04
Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science 2016-11-04
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion 2016-11-03
AMP-Therapeutics–EnBiotix: investment, 201611 acquisition of AMPT via asset acquisition by newly established EnBiotix GmbH 2016-11-03
Merck (DE)–BioMed X: pharma research, 201611– collab Merck expansion funding new cancer research groups at BioMed X 2016-11-03
NBE Therapeutics–Boehringer: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors 2016-11-03
NBE Therapeutics–SEVERAL: investment, 201611 financing round Series B CHF20m led by PPF Group wih BIVF + private investors 2016-11-03
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Bruker–OTHER: nucleic acid diagnostics, 201611 acquisition €na of NAT assays + PCR techn assets in Glasgow for MALDI Biotyper platform 2016-11-02
Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology 2016-11-02
Calibration Technology (IE)–Eppendorf: investment, 201611 acquisition of CTL by Eppendorf 2016-11-01
Q Laboratories–Bruker: mass spectrometer, 201611 supply MALDI Biotyper 2016-11-01
Sotax–Waters: liquid chromatography, 201611– distribution rights for Acquity UPLC H-Class Sytem for pharma labs in several countries for Sotax 2016-11-01
Ganymed–Astellas: investment, 201610– acquisition 100% of Ganymed for €422m upfront + €860m milestones by Astellas Pharma Inc 2016-10-28
Ganymed–Freshfields: legal services, 201610 advisor for Ganymed owners for sale of Ganymed to Astellas 2016-10-28
Mologen–Freshfields: legal services, 201610 advisor for capital increase + convertible bond issue 2016-10-28
BoneSupport–SEVERAL: investment, 201610 raised $47m (SEK327m) in combination of equity + debt finance 2016-10-27
Evolva–ERS Genomics: CRISPR technology, 201610– license ww non-excl €na to CRISPR technology for industrial applications 2016-10-27
Inositec–Halsin Partners: public relations, 201610 service existent by Halsin Partners 2016-10-27
Inositec–SEVERAL: investment, 201610 seed financing round CHF1.4m ($1.42m) from VI Partners via Venture Incubator Fund + Zürcher Kantonalbank 2016-10-27
Cyprotex–Evotec: investment, 201610–201612 acquisition £55.7m=€66.3m in cash for all 26.1m shares + funding of all debt 2016-10-26
Nordic Nanovector–Wilex: antibody-drug conjugates, 201610– collab developm of ADCs for leukemias with Heidelberg Pharma 2016-10-26
NBE Therapeutics–PPF Group: investment, 201610–201611 PPF commits to invest CHF10m in next financing round of NBE as part of collab w Sotio as 2016-10-20
PPF Group–NBE Therapeutics: antibody-drug conjugates, 201610– collab + license agreem of NBE + Sotio as 2016-10-20
Schwabe Pharmaceuticals–ACD/Labs: cheminformatics, 201610– supply deployment of ACD/Spectrus platform by Willmar Schwabe Pharmaceuticals 2016-10-19
ADC Therapeutics–SEVERAL: investment, 201610 private financing round $105m incl Auven Therapeutics + Wild Family Office + AstraZeneca 2016-10-18
Science 37–Novartis: investment, 201610 financing round Series B totalling $31m incl existing + co-investor dRx Capital 2016-10-18
Science 37–SEVERAL: investment, 201610 financing round Series B $31m led by Redmile Group + incl Lux Capital + dRx Capital + SGBV 2016-10-18
Hookipa–Austria (govt): grant, 201610 5th FFG grant €4.16m to develop arenavirus vector-based cancer immunotherapies 2016-10-17
ObsEva–SEVERAL: investment, 201610–201701 IPO $96.75m+$14.513m w 645k+967.5k common shares at $15/share at Nasdaq Global Select Market 2016-10-17
Max Planck–Labfolder: electronic lab notebook, 201610– supply license for up to 11k MPI researchers using Labfolder s/w 2016-10-12
UgiSense–SEVERAL: investment, 201610 first financing round €1.2m from private investors 2016-10-12
Merck (DE)–HTG: molecular companion diagnostics, 201610– collab master CDx agreement with HTG Molecular Diagnostics 2016-10-11
Helsinn–Consilium: public relations, 201610 service existent by CSC 2016-10-10
Mei Pharma–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
OncoResponse–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
QuantuMDx–Helsinn: investment, 201610 existent as one of the first investments of new Helsinn Investment Fund SA 2016-10-10
Selexis–Sam Brown: public relations, 201610 service existent by Sam Brown Inc 2016-10-10
Newron–SEVERAL: investment, 201610 capital increase CHF26.1m private placement 1.32m new shares at CHF19.75/share 2016-10-06
Kibion–Mayoly Spindler: investment, 201610 acquisition of Kibion AB by Mayoly Spindler 2016-10-05
Probiodrug–SEVERAL: investment, 201610 capital increase €14.9m w 744k new shares at €20/share representing 10% of issued share capital 2016-10-05
Carrick Therapeutics–Evotec: drug discovery services, 201610– collab strategic alliance discovery + preclinical services for novel oncology targets 2016-10-04
Carrick Therapeutics–Evotec: investment, 201610 1st financing round totalling $95m incl up to $6m from co-investor Evotec AG 2016-10-03
Carrick Therapeutics–SEVERAL: investment, 201610 1st financing round $95m co-led by ARCH Venture Partners + Woodford Investment 2016-10-03
Bellevue–SEVERAL: investment, 201610–201612 initial offering £150m + listing at LSE of BB Healthcare Trust plc managed by Bellevue Asset Management AG 2016-10-01
Depomed–Grünenthal: pain drug, 201609 collab existent cebranopadol developm + marketing rights for US for Depomed 2016-09-30
EngMab–Celgene: investment, 201609 acquisition of EngMab AG for $600m 2016-09-30
Noxxon–OTHER: investment, 201609 listing of ordinary shares on Alternext Paris [no new shares issued] 2016-09-30
Noxxon–SEVERAL: investment, 201609 private placement just prior to listing of ordinary shares on Alternext Paris 2016-09-30
Bluebird Bio–Medigene: TCR technology, 201609– collab strategic alliance $15m upfront + up to over $1b funding/milestones + royalties 2016-09-29
Boehringer–Hospital Corp of America: clinical research, 201609– collab clinical developm of combi of 2 checkpoint inhibitors w Sarah Cannon Research 2016-09-29
ICMP–Qiagen: MDx forensics, 201609– collab developm NGS workflow for identification of missing persons 2016-09-29
Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products 2016-09-28
Immunic–4SC: immune modulatory compounds, 201609 acquisition of small molecule immunology portfolio of 4SC by Immunic 2016-09-28
Noxxon–NewCap: public relations, 201609 service existent by NewCap 2016-09-28
Immunic–Bavaria (govt): investment, 201609 financing round Series A totalling €17.5m incl co-investor Bayern Kapital 2016-09-27
Immunic–High-Tech Gründerfonds: investment, 201609 financing round Series A totalling €17.5m incl co-investor HTGF 2016-09-27
Immunic–Life Sciences Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners 2016-09-27
Immunic–LifeCare Partners: investment, 201609 financing round Series A totalling €17.5m co-led by LSP V + LifeCare Partners 2016-09-27
Immunic–SEVERAL: investment, 201609 financing round Series A €17.5m co-led by LSP + LifeCare Partners 2016-09-27
NeuRoWeg project–Grünenthal: companion diagnostics, 201609– Grünenthal is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–Life & Brain: companion diagnostics, 201609– Life & Brain GmbH is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–North Rhine-Westphalia (govt): grant, 201609– EFRD/NRW €1.5m grant to develop test for efficacy of neuropathic pain drugs 2016-09-27
NeuRoWeg project–Univ Bonn: companion diagnostics, 201609– Univ Hospital Bonn is partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
NeuRoWeg project–Univ Cologne: companion diagnostics, 201609– Univ Hospital Cologne partner in project for efficacy tests for neuropathic pain drugs 2016-09-27
next pagenext page 1 2 3 ... 25 26 27 ... 29 30 31  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px

» top